ScripGilead Sciences’ lenacapavir is already expected to have a significant advantage among injected HIV drugs thanks to its twice-yearly injection schedule when the company launches it for pre-exposure pr
ScripIf biopharma companies keep up the pace of three initial public offerings in the US per month seen in January, the number of IPOs in 2025 will exceed the 25 first-time offerings that drug developers a
In VivoLawrence Miller is not afraid of giants. The CEO of sleep apnea-focused Apnimed believes that even though Eli Lilly’s Zepbound (tirzepatide) recently won approval for treating moderate-to-severe obstr
ScripIt has been less than three years since Atlas Venture closed its thirteenth venture capital fund and one thing is unchanged with its fourteenth – the size of the fund. Atlas announced on 5 December th